The ambr 250 is a mini bioreactor system for parallel fermentation or cell culture.
On June 15, 2016, Sartorius Stedim Biotech introduced the ambr 250 mini benchtop bioreactor system for parallel fermentation or cell culture. This system combines a unique single-use bioreactor vessel and expandable system design for process development, the company said in a press announcement.
The new ambr 250 modular system consists of a workstation with two, four, six, or eight single-use bioreactors, with a working volume range of 100â250 mL. These mini bioreactors, based on the same stirred tank bioreactors in the high throughput system, contain impellers suitable for fermentation or cell culture and scale up to larger bioreactors. They are also fully integrated with liquid reservoirs and syringe pumps, allowing rapid experimental set up and turn around, thus significantly increasing lab efficiency.
Once installed, the bioreactor has all the required process services for parameter control, including pH, DO, temperature, and agitation. Feeds can also be delivered from the reagent reservoirs via syringe pumps into the bioreactor. One control unit is capable of controlling up to eight bioreactor stations independently using a touch screen user interface.
Source: Sartorius Stedim Biotech
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.